North America Human Growth Hormone Market – Segmented By Product (Long Acting, Others), By Application (Growth Hormone (GH) Deficiency, Turner Syndrome, Idiopathic Short Stature, Prader-Willi Syndrome, Small for Gestational Age, Other), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Specialty Pharmacy), By Region, Competition, Forecast, Opportunities, 2018-2028

Published Date: November - 2024 | Publisher: MIR | No of Pages: 320 | Industry: Healthcare | Format: Report available in PDF / Excel Format

View Details Buy Now 2890 Download Sample Ask for Discount Request Customization

North America Human Growth Hormone Market – Segmented By Product (Long Acting, Others), By Application (Growth Hormone (GH) Deficiency, Turner Syndrome, Idiopathic Short Stature, Prader-Willi Syndrome, Small for Gestational Age, Other), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Specialty Pharmacy), By Region, Competition, Forecast, Opportunities, 2018-2028

Forecast Period2024-2028
Market Size (2022)USD 1.99 billion
CAGR (2023-2028)12.29%
Fastest Growing SegmentGrowth Hormone Deficiency
Largest MarketNorth America

MIR Consumer Healthcare

Market Overview

North America Human Growth Hormone Market has valued at USD 1.99 billion in 2022 and is anticipated to project robust growth in the forecast period with a CAGR of 12.29% through 2028. The Human Growth Hormone Market has witnessed steady growth over the years. Factors contributing to this growth include the increasing awareness of the importance of early diagnosis and treatment of growth hormone deficiencies, biopharmaceutical innovation, and the expansion of treatment options for rare conditions. The market is expected to continue growing, driven by innovations in biotechnology, increasing prevalence of hormone deficiencies, and advances in personalized medicine.

Key Market Drivers

Increased Awareness and Diagnosis

Increased awareness and diagnosis play a critical role as a market driver for the growth of the North America Human Growth Hormone Market

The awareness of growth hormone deficiencies is not limited to children. There is a growing recognition of hormone deficiencies in adults as well. Adult growth hormone deficiency can be linked to various health issues, and with increased awareness, more adults are seeking medical evaluation and treatment. This expansion of the patient base into the adult population further drives market growth. Many government and non-governmental health organizations have launched awareness campaigns and health initiatives that focus on growth hormone deficiencies. These initiatives include the dissemination of educational materials, the organization of health camps, and partnerships with healthcare providers to promote early diagnosis and treatment. These efforts have a profound impact on raising awareness and encouraging individuals to seek medical attention. The involvement of the medical community is crucial in driving awareness and diagnosis. Healthcare professionals, including pediatricians, endocrinologists, and primary care physicians, play a pivotal role in recognizing symptoms, referring patients for diagnostic testing, and initiating treatment. The medical community's increased awareness and commitment to early diagnosis enhance the effectiveness of this driver.

Biopharmaceutical Innovation

Biopharmaceutical innovation is a significant market driver for the growth of the North America Human Growth Hormone Market.

Biopharmaceutical companies continually introduce new and improved growth hormone therapies to the market. These innovations offer healthcare providers and patients a broader range of therapeutic options to choose from, tailored to specific needs and preferences. Such enhancements expand the market's product portfolio and cater to diverse patient populations. Innovations in drug delivery systems have enhanced patient convenience and compliance. For instance, long-acting growth hormone formulations have been developed, reducing the frequency of administration, which is particularly beneficial for patients. These systems increase patient adherence to treatment plans, further fueling market growth. Ongoing biopharmaceutical innovation focuses on enhancing the safety and efficacy of growth hormone therapies. New formulations are designed to minimize side effects and reduce the potential for adverse reactions. Improved safety profiles are attractive to healthcare providers and patients alike, increasing the adoption of these therapies.


MIR Segment1

Regulatory Approvals

Regulatory approvals play a pivotal role as a market driver for the growth of the North America Human Growth Hormone Market.

Regulatory approvals lead to increased adoption of approved growth hormone therapies. Healthcare providers are more likely to recommend treatments that have undergone thorough evaluation and received official endorsements. Patients are also more inclined to accept these therapies, as they believe in the safety and efficacy of approved products. Regulatory approvals often expand the target patient population for a particular growth hormone therapy. For example, an approval for a pediatric growth hormone therapy may later be extended to include adults with hormone deficiencies, broadening the market's reach and revenue potential. Products that receive regulatory approval gain a competitive advantage in the market. They stand out as trusted and legitimate treatments, positioning themselves ahead of non-approved or generic alternatives. This competitive edge can drive market share and growth.

Research in Rare Conditions

Research in rare conditions is a significant market driver for the growth of the North America Human Growth Hormone Market.

Research in rare conditions expands the potential patient population for growth hormone therapies. While these conditions individually affect a relatively small number of people, the cumulative impact is substantial. As tailored therapies are developed and researched, they become found at to patients who may have previously had limited or no treatment options. Many growth hormone therapies developed for rare conditions receive orphan drug designations from regulatory authorities. These designations provide certain incentives to pharmaceutical companies, such as extended market exclusivity and financial incentives, to develop treatments for rare diseases. This encourages research and innovation in this area. Pharmaceutical companies increasingly recognize the market growth opportunities in rare conditions. While each rare condition may have a small patient population, the combined market potential across various rare conditions is substantial. Companies invest in research and development to tap into these underserved markets and offer specialized treatments.

Key Market Challenges

High Treatment Costs

Growth hormone therapies are often costly, and the expenses can be a significant burden on patients and healthcare systems. The high cost of therapy can limit accessibility for many patients, particularly those without adequate insurance coverage.

Healthcare Budget ConstraintsIn many countries, healthcare budgets are limited, and the cost-effectiveness of growth hormone therapies is a consideration for policymakers and healthcare providers. Cost constraints may lead to restricted access to these therapies, potentially slowing down market growth.

Challenges in Emerging MarketsIn emerging economies, affordability is a considerable concern. The cost of growth hormone therapies can be prohibitively high for a large portion of the population, limiting market expansion in these regions.


MIR Regional

Regulatory Hurdles

The process of obtaining regulatory approvals for new growth hormone therapies can be lengthy and costly. Stringent requirements by regulatory authorities demand extensive clinical data, leading to prolonged development timelines.

While orphan drug designation can provide incentives for developing therapies for rare conditions, it also poses challenges. Meeting orphan drug designation criteria may limit the patient population that can benefit from the therapy, affecting market potential. Variations in regulatory processes and requirements across countries can create barriers for market entry and expansion, particularly for smaller biopharmaceutical companies.

Limited Awareness and Diagnosis

Underdiagnosis of Growth Hormone DeficienciesDespite awareness efforts, there are still challenges in diagnosing growth hormone deficiencies. This underdiagnosis can lead to missed treatment opportunities, limiting the patient pool and market growth. The effectiveness of awareness programs can vary by region. In some areas, there may be limited access to educational initiatives, resulting in lower awareness levels and, subsequently, delayed diagnosis and treatment.

Stigma and misconceptions surrounding growth hormone therapies can impede patient willingness to seek treatment. Concerns about side effects or perceived health risks may deter some individuals from pursuing therapy, affecting market growth.

Key Market Trends

Biotechnology Advancements

One significant trend in the market is the continued advancement of recombinant technologies. Recombinant DNA techniques enable the production of synthetic growth hormones that closely mimic the body's natural growth hormone. These biotechnological advances have led to safer and more effective treatments, improving patient outcomes.

Biotechnology has enabled the development of targeted growth hormone therapies for specific patient populations. This trend includes the creation of treatments tailored for conditions like Turner syndrome, Prader-Willi syndrome, and pediatric growth disorders. Targeted therapies enhance the precision and effectiveness of treatments, meeting the unique needs of these populations.

Telemedicine and Remote Monitoring

The COVID-19 pandemic accelerated the adoption of telemedicine in healthcare, including the management of growth hormone deficiencies. Patients can now consult with healthcare providers remotely, which enhances access to specialized care, particularly in regions with limited healthcare infrastructure. Telemedicine offers convenience and the potential for increased diagnosis and treatment rates.

Remote monitoring technology, such as wearable devices, is increasingly used to track patient response to growth hormone therapies. These devices allow healthcare providers to remotely assess treatment compliance and effectiveness. This trend aids in personalized treatment adjustments and data-driven decision-making.

Orphan Drug Development

Pharmaceutical companies are increasingly focusing on orphan drug development for rare genetic conditions associated with growth hormone deficiencies. These conditions, such as Turner syndrome and Prader-Willi syndrome, may individually have a small patient population, but collectively represent a substantial market. The development of specialized treatments for these rare conditions is a growing trend in the market.

Regulatory authorities grant orphan drug designation to therapies developed for rare diseases. This designation provides certain incentives to pharmaceutical companies, such as extended market exclusivity and financial support, encouraging the development of treatments for rare conditions. This trend promotes innovation in addressing unmet medical needs.

Segmental Insights

Product Insights

Based on the category of Product, the Others segment emerged as the dominant player in the North America market for Human Growth Hormone in 2022. This particular segment is anticipated to maintain a steady growth rate throughout the forecast period. Other segments within the market encompass short-acting and intermediate-acting growth hormones. The short-acting and intermediate-acting segment is poised for significant traction in the coming years due to the rising incidence of insufficiency and the availability of diverse products such as Genotropin (Pfizer Inc.), Humatrope (Eli Lilly & Co.), Saizen (Merck & Co. Inc.), and Norditropin (Novo Nordisk A/S), among others.

Recent product launches and the increased adoption of short-acting preparations, which tend to have fewer side effects, are additional factors contributing to the expansion of this segment. On the other hand, the long-acting segment is expected to register the fastest growth rate during the forecast period. This growth is driven by advantages like reduced administration frequency, enhanced patient compliance, and convenience.

The robust investigational pipeline and recent product launches are fueling the growth of this segment. For instance, in January 2022, Ascendis Pharma A/S announced European Commission approval for the marketing authorization of SKYTROFA, aimed at treating growth failure in children and adolescents aged 3 to 18. These factors are expected to drive the growth of this segment.

Application Insight

Distribution Channel Insights

The hospital pharmacy segment is projected to experience rapid growth during the forecast period. The growing incidence of the ailment, more frequent hospital visits, and advantageous reimbursement policies are fueling the utilization of this sector. Additionally, patients are increasingly favoring recombinant and synthetic HGH, which is easily accessible in hospital pharmacies. These elements are contributing to the expansion and utilization of this field. The online pharmacy category is poised for swift growth in the forthcoming years. These factors collectively contribute to the growth of this segment.

Regional Insights

United States emerged as the dominant player in the North America Human Growth Hormone market in 2022, holding the largest market share in terms of value. The growth of the regional market is expected to be driven by heightened healthcare awareness among the population, significant government initiatives, and favorable reimbursement policies. Additionally, increasing research and development activities, ample research funding, and the presence of organizations dedicated to raising awareness and improving treatment rates are anticipated to contribute to the region's market expansion. Furthermore, the strong presence of key industry players, such as Pfizer Inc. and Lilly, is projected to bolster the region's growth. In Europe, the second-largest market share is attributed to factors such as the rising prevalence of growth hormone deficiencies, the availability of synthetic growth hormones, and extensive research and development efforts in the region.

The Canada market is poised to be the fastest-growing market, offering lucrative growth opportunities for Human Growth Hormone players during the forecast period. Factors such as stress, insufficient sleep, and low glucose levels affect individuals. For instance, in 2021, the European Medicines Agency reported that growth hormone deficiency affected approximately 4.7 out of 10,000 individuals in the Canadian Population. Among European countries, Germany leads the market, while France is expected to achieve the highest compound annual growth rate (CAGR) from 2023 to 2030

Recent Developments

  • InOctober 2023 - Novo Nordisk to acquire ocedurenone for uncontrolledhypertension from KBP Biosciences.
  • InSeptember 2023, Eli Lilly and Company announces that the FDA has approvedTyvyt® (sintilimab injection) for the treatment of adults with relapsed orrefractory (R/R) large B-cell lymphoma (LBCL) after at least two prior lines ofsystemic therapy, including an anthracycline-containing chemotherapy regimenand rituximab.   
  • InSeptember 2023, European Commission approves Pfizer's LITFULOâ„¢ for adolescentsand adults with severe alopecia areata.

Key Market Players

  • NovoNordisk A/S
  • Eli Lilly and Company
  • Pfizer, Inc.
  • Sandoz International GmbH (Novartis AG)
  • Genentech, Inc. (Roche)
  • Merck KGaA
  • Ferring Pharmaceuticals
  • Ipsen
  • Teva Pharmaceutical Industries, Ltd.

 By Product

By Application

By Distribution Channel

By Region

  • Long Acting
  • Others

 

  • Growth Hormone (GH) Deficiency
  • Turner Syndrome
  • Idiopathic Short Stature
  • Prader-Willi Syndrome
  • Small for Gestational Age
  • Other
  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy
  • Specialty Pharmacy
  • United States
  • Canada
  • Mexico

Table of Content

To get a detailed Table of content/ Table of Figures/ Methodology Please contact our sales person at ( chris@marketinsightsresearch.com )

List Tables Figures

To get a detailed Table of content/ Table of Figures/ Methodology Please contact our sales person at ( chris@marketinsightsresearch.com )

FAQ'S

For a single, multi and corporate client license, the report will be available in PDF format. Sample report would be given you in excel format. For more questions please contact:

sales@marketinsightsresearch.com

Within 24 to 48 hrs.

You can contact Sales team (sales@marketinsightsresearch.com) and they will direct you on email

You can order a report by selecting payment methods, which is bank wire or online payment through any Debit/Credit card, Razor pay or PayPal.